A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2020

Primary Completion Date

October 26, 2023

Study Completion Date

October 26, 2023

Conditions
Ulcerative Colitis
Interventions
DRUG

PF-06826647 100 mg QD

Investigational Product

DRUG

PF-06826647 300 mg QD

Investigational Product

DRUG

PF-06826647 600 mg QD

Investigational Product

DRUG

Placebo

Matched Placebo

DRUG

PF-6826647 400 mg QD

Investigational Product

Trial Locations (24)

22031

Gastroenterolgy Associates of Northern Virginia, Fairfax

Gastroenterology Associates of Northern Virginia, Fairfax

Verity Research, Inc., Fairfax

22033

Fair Oaks Imaging Center- Reston Radiology Consultants, Fairfax

22192

Associates in Gastroenterology (c/o TrialSpark, inc), Woodbridge

30076

Gastroenterology Consultants P.C., Roswell

33165

Saludmax Medical Corp., Miami

33615

Alliance Clinical Research of Tampa, Tampa

46410

Internal Medicine Associates (c/o TrialSpark, Inc.), Merrillville

77063

Physicians Ambulatory Surgery Center, LLC, dba Physicians Endoscopy Center, Houston

77074

Houston Digestive Diseases Consultants, P.A., Houston

Memorial Hermann SW Surgery Center, Houston

77479

Sugar Lakes Family Practice, PA, Sugar Land

78230

Gastroenterology Consultants of San Antonio, San Antonio

Victorium Clinical Research, San Antonio

78258

South Texas Radiology Imaging Center, San Antonio

90301

ADVA Clinical Research, Inglewood

Centinela Valley Endoscopy Center, Inglewood

Inglewood Imaging Center, Inglewood

91303

Hope Clinical Research, Canoga Park

91325

Renaissance Imaging Center (CT/Xray), Northridge

91356

Valley Endoscopy Center (Colonoscopy/Flexible sigmoidoscopy), Tarzana

92660

Surinder Saini, M.D., Inc., Newport Beach

07013

Gastroenterology Associates of New Jersey, LLC (c/o TrialSpark, Inc.), Clifton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04209556 - A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis | Biotech Hunter | Biotech Hunter